Dexchlorpheniramine has been assigned to category B by the FDA. Animal studies have failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. Dexchlorpheniramine has limited data from the manufacturer to suggest a recommendation for use during pregnancy.

Antihistamine exposure during the last two weeks of pregnancy has been associated with general and retrolental fibroplasia in premature infants.

See references

Dexchlorpheniramine is excreted into human milk. Side effects of antihistamine use have been described as a higher risk in infants, newborns, and premature babies than in the general population. The manufacturer recommends that due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

See references